Response and Resistance Mechanisms of RAS Inhibitors in KRAS-Mutant NSCLC Research Background With the clinical development of RAS inhibitors, the treatment of KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) faces a new turning point. However, in clinical practice, patients show poor long-term responses to RAS inhibitors, influencing clinical effica...
title: “Utilizing Clonal Lineage Tracing with Recordable Barcodes Unveils the Migration History of Prostate Cancer Metastasis” author: Ryan N. Serio, Armin Scheben, *Billy Lu, *Domenic V. Gargiulo, Lucrezia Patruno, Caroline L. Buckholtz, Ryan J. Chaffee, Megan C. Jibilian, Steven G. Persaud, Stephen J. Staklinski, Rebecca Hassett, Lise M. Brault, ...
This study reveals a new targetable cancer subtype characterized by activating point mutations in the MET tyrosine kinase domain (TKD). Researchers identified MET TKD activating mutations in approximately 0.5% of patients across a genomic data set of over 600,000 cancer cases, encompassing various tumor types, with the highest prevalence in renal c...
Iron (Ferric Ion, Fe3+)-Dependent Telomerase Reactivation Drives Colorectal Cancer Development I. Research Background Colorectal Cancer (CRC) is the third most common cancer globally, involving both genetic and non-genetic factors in its pathogenesis. Existing research shows a significant association between high iron content, hereditary iron overl...
High-Throughput Discovery of MHC Class I and II Restricted T Cell Epitopes Using a Novel Synthetic Cellular Circuit Research Background and Issues In recent years, antigen discovery technologies have made remarkable progress, especially in the application of human T-cell receptors (TCRs) in the recognition of major histocompatibility complex (MHC) ...
Spatially Isolated Macrophage Populations Predict Different Outcomes in Colon Cancer Introduction Macrophages are sentinel immune cells in tissues, performing a variety of functions including pathogen defense, antigen presentation, phagocytosis of dead cells, and the secretion of signals that drive tissue repair. In tumors, macrophage infiltration ...
Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...
AAV-SB-CRISPR Screening Identifies Genetic Checkpoints in Tumor-Infiltrating Primary Natural Killer Cells for CAR-NK Therapy With the rapid advancement of biotechnology and gene editing technologies, increasing attention is being paid to enhancing the clinical potential of natural killer (NK) cells in cancer therapy. Despite their potential in clin...
Application of Base Editing Screening Technology in Tumor Immunotherapy T Cell Research Immune cell therapies, such as T cell transfer therapy and CAR T cell therapy, have become important clinical cancer treatment tools in certain disease fields. However, most cancer patients fail to benefit from cell therapies, possibly due to inherent changes in...
Engineering Selective Gene Drives to Steer Tumor Evolution to Counteract Drug Resistance As tumors evolve, targeted therapies against cancer often fail due to the evolution of drug resistance. This study demonstrates a way to manipulate tumor evolution repeatedly to design therapeutic opportunities, even in the presence of genetic heterogeneity. We...